MyoD family inhibitor domain containingGenealiases: HIC · LMPHM12 · MDFIC1
Q-omics provides the consensus-scored MDFIC profile across patient tissues and cancer cell-line models. MDFIC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MDFIC is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MDFIC RNA expression shows 19,386 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ESCA, KIRC, and UVM as cancer lineages where MDFIC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDFIC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDFIC survival associations across molecular data types. MDFIC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDFIC RNA expression–survival associations across cancer types. High MDFIC expression shows unfavorable associations in KIRP and LGG, but favorable associations in ESCA, SKCM, BRCA and MESO. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for MDFIC RNA expression.
This table summarizes MDFIC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MDFIC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDFIC shows lower tumor expression in UCEC, COAD, BRCA and LUSC and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher MDFIC RNA expression in tumor versus normal tissue (log2 FC = +0.617, t-test p < 0.001).
This table shows molecular features associated with MDFIC in patient tissues and cancer cell lines. In patient samples, MDFIC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MDFIC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SKIN.
